| CLINICAL STUDY |
At the end of 1999, evidence from the initial phase II trial of AG7088 in volunteers given experimentally induced rhinovirus infection indicated that the drug could significantly improve cold symptoms. The placebo-controlled, randomised, double-blind trial involved susceptible volunteers who received multiple daily intranasal doses of AG7088 24 hours after deliberate exposure to human rhinovirus. Compared with placebo-treated volunteers, those treated with AG7088 experienced a significant reduction in total cold symptoms, respiratory symptom scores, rhinovirus concentrations in the upper respiratory tract and cumulative nasal mucous production. AG7088 was generally well tolerated in this study, consistent with earlier safety data
|